EU Insulin Battle Looms After EMA Panel Backs Novo’s Insulin Degludec
This article was originally published in The Pink Sheet Daily
Europe’s top drug advisory panel, CHMP, gave backing to Novo Nordisk’s new long-acting insulin analog as well as to new therapies from Astellas and Savient for urinary incontinence and severe gout.
You may also be interested in...
The Danish pharma is focused on the latest formulation technology for insulin and GLP-1 and combinations thereof to sustain its diabetes market leader position. It’s not particularly worried about biosimilars, despite two of its top sellers coming off-patent in the next few years.
Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.